Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Day One Biopharmaceuticals, Inc.
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Oversubscribed $175.0 Million Private Placement
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
June 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Sale of Priority Review Voucher for $108 Million
May 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
May 06, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
February 26, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Two New Appointments to Board of Directors
January 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
November 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 30, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
August 07, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Pricing of Public Offering of Common Stock
June 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Proposed Public Offering of Common Stock
June 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
June 04, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
May 30, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
May 01, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
April 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
March 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
January 08, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
DAWN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.